Go to deals
Healthcare

Tem Group has been acquired by Instrumentation Laboratory

The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.

TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.

IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.

"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."

Oaklins' team in Switzerland advised the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

Dr. Roberto  Tracia

Dr. Roberto Tracia

Partner

Bern, Switzerland
Oaklins Switzerland
 Daniel  Vogel

Daniel Vogel

Director

Zurich, Switzerland
Oaklins Switzerland
 David  Zürrer

David Zürrer

Senior Associate

Basel, Switzerland
Oaklins Switzerland
Dr. Peter M. Binder

Dr. Peter M. Binder

Bern, Switzerland
Oaklins Switzerland

Related deals

Enterprises ImportFab Inc. has been acquired by Labomar S.p.A
Healthcare

Enterprises ImportFab Inc. has been acquired by Labomar S.p.A

Labomar S.p.A., a leading company in the research, development and production of food supplements, medical devices and foods for specific medical and cosmetic purposes, has acquired Enterprises ImportFab Inc., a Canadian firm based in Montréal that operates in the North American pharmaceutical, cosmetic and nutraceutical market. The operation has been carried out in partnership with SIMEST that will participate in the acquisition and will hold a minority share of the Canadian company.

Learn more
Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance
Healthcare

Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance

Groupe Serenis has raised US$8 million in equity from BNP Paribas Developpement, Credit Agricole GSO Capital and Multicroissance Banque Populaire Occitane.

Learn more
Laboratório S. José has been acquired by SYNLAB
Business Support Services | Healthcare

Laboratório S. José has been acquired by SYNLAB

The private shareholders of Laboratório S. José have sold the company to SYNLAB.

Learn more